|Multiple Myeloma |
Early findings from a phase III clinical trial showed that patients with multiple myeloma who received an autologous stem cell transplant survived longer without disease progression than those who received only chemotherapy using novel agents.
The study was the largest reported aimed at comparing ASCT with a bortezomib-based regimen alone in patients younger than 65, and will be presented at this year’s annual meeting of the American Society of Clinical Oncology, June 3-7 in Chicago.
“Even in an age of novel therapies, proven approaches can retain their value. This study demonstrated that combining the best of both worlds—initial therapy with a novel agent followed by stem cell transplant—resulted in the best patient outcomes,” said ASCO President Julie Vose in a statement.